Tactile Systems Technology Inc Forecasts Earnings of 11 Cents Per Share for Q2 2025
Tactile Systems Technology Inc (NASDAQ: TCMD), a medical device company based in Minneapolis, Minnesota, is set to report its financial results for the quarter ended June 30, 2025, on August 4, 2025. According to consensus estimates from five analysts compiled by LSEG Refinitiv data, the company is expected to post earnings of 11 cents per share.
Revenue Growth Anticipated
The company is projected to report a slight increase in revenue for the quarter, with estimates indicating a 1.0% rise year-over-year. Revenue is expected to grow from approximately $73.22 million in Q2 2024 to around $73.93 million in the current quarter. This growth aligns with the company’s own guidance provided on May 5, 2025, which forecasted revenues between $73.00 million and $76.00 million for the same period.
Analyst Recommendations and Price Targets
The average analyst recommendation for Tactile Systems shares currently stands at "hold." Among the five analysts surveyed, there is one rating it as either a "strong buy" or "buy," and four advising to "hold." No sell or strong sell recommendations were noted. The 12-month median price target on Wall Street is $13.00 per share, representing approximately a 23.2% increase from the last closing price of $9.98. ### Recent Earnings Performance Context
Historically, Tactile Systems has shown a pattern of mixed earnings results. For instance, in the most recent reported quarter ending March 31, 2025, the company missed earnings estimates, posting a loss of 13 cents per share against expectations of a 7-cent loss. However, prior quarters saw the company beat earnings estimates considerably, including a strong outperformance of 81.8% in Q4 2023 and a remarkable 3,257.1% beat in Q3 2023. This historical volatility underscores the importance of the upcoming earnings release for investors seeking clarity on the company’s operational momentum.
About Tactile Systems Technology Inc
Tactile Systems Technology Inc develops and markets medical devices primarily designed for chronic disease management. The company’s technologies and therapies focus on conditions such as lymphedema and chronic venous insufficiency, providing non-invasive treatment options. As it advances its product offerings and expands market reach, financial results such as these are closely watched by analysts and investors alike.
Looking Ahead
Investors and market observers will monitor the company’s Q2 earnings release closely on August 4 to assess actual financial performance versus analyst expectations. The reported earnings per share, revenue figures, and any updated guidance provided by management may influence share price movements and investor sentiment in the near term.
This report is based on data available as of August 1, 2025, 20:20 GMT. All financial values are reported in U.S. dollars unless otherwise stated.
For further information or inquiries regarding this earnings preview, please contact Estimates.Support@lseg.com.
© Copyright Thomson Reuters 2025. All rights reserved.
